Further investigations into the relationship between METTL3 and tumor-infiltrating DCs, as well as other innate immune cells in TME, can significantly enhance our comprehension of the regulatory mechanisms governing innate immunity within TME and can pave the way for reshaping TME for cancer therapy. The gene discussed is METTL3; the disease is cancer.